Business Context and Reporting Period
This Form 8-K Current Report was filed by Cartesian Therapeutics, Inc. on March 26, 2026. The report discloses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
The material change reported is the resignation of Murat Kalayoglu, M.D., Ph.D., from the Board of Directors. His resignation is effective March 31, 2026. Dr. Kalayoglu served on the Board since 2023 and held roles as Chairman of the Science and Technology Committee and a member of the Nominating and Corporate Governance Committee. The Company states the resignation is not the result of any disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The departure is described as the director pursuing other opportunities.
Key Facts for Investors to Verify
- Confirmation of the effective date of Dr. Kalayoglu's resignation (March 31, 2026).
- Whether the Company has announced a replacement director or a new committee structure.
- Any potential impact on the Company's Science and Technology Committee operations.